Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis

NCT03312751 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hemophagocytic Lymphohistiocytosis

Interventions

DRUG: Emapalumab

Sponsor

Swedish Orphan Biovitrum